未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)一项Becotatug（JMT101）联合奥希替尼（Osi）治疗经典EGFR突变非小细胞肺癌（NSCLC）患者的II期研究（BOOSTER研究）
Zhang, L.; Fang, W. F.; Zhao, S.; Yu, Y.; Yong, T. X.; Dong, X.; Zhuang, W.; Hu, Y.; Luo, F.; Wang, Q.; Chu, Q.; Fu, Z.; Yao, Y.; Ma, X.; Ding, C.; Hao, J.; Yang, X.; Wan, X.; Li, M.; Yang, Y. 分享 收藏 LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 proteinCai, Zijie; Shi, Qianfeng; Li, Yudong; Jin, Liang; Li, Shunying; Wong, Lok Lam; Wang, Jingru; Jiang, Xiaoting; Zhu, Mengdi; Lin, Jinna; Wang, Qi; Yang, Wang; Liu, Yujie; Zhang, Jun; Gong, Chang; Yao, Herui; Yao, Yandan; Liu, Qiang 分享 收藏 分享 收藏 分享 收藏 分享 收藏 CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype来自肿瘤相关巨噬细胞的CCL18信号激活成纤维细胞采取化学抗性诱导表型Zeng, Wenfeng; Xiong, Lixiong; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Zhang, Mengmeng; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di 分享 收藏 AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)Yu, Y.; Huang, D.; Gao, B.; Zhao, J.; Hu, Y.; Zhuang, W.; Kao, S.; Xu, W.; Yao, Y.; Yang, T-Y.; Lee, Y.; Kim, J-S.; Shiah, H-S.; Wang, R.; Zheng, H.; Tan, W.; Gao, R.; Kim, H. R.; Lu, S. 分享 收藏 Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer (vol 7, 100395, 2022)Ren, S.; Wang, J.; Ying, J.; Mitsudomi, T.; Lee, D. H.; Wang, Z.; Chu, Q.; Mack, P. C.; Cheng, Y.; Duan, J.; Fan, Y.; Han, B.; Hui, Z.; Liu, A.; Liu, J.; Lu, Y.; Ma, Z.; Shi, M.; Shu, Y.; Song, Q.; Song, X.; Song, Y.; Wang, C.; Wang, X.; Wang, Z.; Xu, Y.; Yao, Y.; Zhang, L.; Zhao, M.; Zhu, B.; Zhang, J.; Zhou, C.; Hirsch, F. R. 分享 收藏 分享 收藏 The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancerLu, S.; Pan, H.; Wu, L.; Yao, Y.; He, J.; Wang, Y.; Wang, X.; Wang, X.; Cai, X.; Yu, Y.; Ma, Z.; Min, X.; Yang, Z.; Cao, L.; Yang, H.; Shu, Y.; Zhuang, W.; Cang, S.; Fang, J.; Li, K. 分享 收藏 分享 收藏 Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial依维莫司联合来曲唑与氟尿嘧啶，表柔比星和环磷酰胺治疗ER阳性HER2-negative乳腺癌的新辅助治疗: 一项随机试验Wu, Wei; Chen, Jiewen; Deng, Heran; Jin, Liang; He, Zhanghai; Rao, Nanyan; Nie, Yan; Yao, Yandan; Yang, Yaping; Su, Fengxi; Liu, Jieqiong 分享 收藏 分享 收藏 Patient controlled analgesia (PCA) versus non-pca intravenous hydromorphone for severe cancer pain: Update from a multi-center, phase III randomized trial, HMORCT09-1Lin, R.; Lin, S.; Zhu, J.; Feng, S.; Wu, Q.; Fu, J.; Wang, F.; Li, H.; Li, X.; Zhang, G.; Yao, Y.; Xin, M.; Lai, T.; Lv, X.; Chen, Y.; Lin, Y.; Hong, L.; Lin, S.; Zhao, S.; Huang, C. 分享 收藏 分享 收藏 Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR CascadeLin, Xiaorong; Dinglin, Xiaoxiao; Cao, Siting; Zheng, Senyou; Wu, Cheng; Chen, Wenying; Li, Qingjian; Hu, Qian; Zheng, Fang; Wu, Zhiyong; Lin, De-Chen; Yao, Yandan; Xu, Xiaoding; Xie, Zhi; Liu, Qiang; Yao, Herui; Hu, Hai 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
OAAI